Morgan Stanley Cuts Fractyl Health (NASDAQ:GUTS) Price Target to $10.00

Fractyl Health (NASDAQ:GUTS) had its price objective trimmed by Morgan Stanley from $18.00 to $10.00 in a report issued on Monday,Benzinga reports. The firm currently has an overweight rating on the stock.

Fractyl Health Stock Up 7.2 %

Shares of GUTS opened at $1.64 on Monday. Fractyl Health has a 52 week low of $1.52 and a 52 week high of $11.55. The firm has a market cap of $78.88 million and a P/E ratio of -0.13. The firm’s 50-day simple moving average is $2.03 and its 200 day simple moving average is $2.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The company had revenue of $0.01 million during the quarter. On average, analysts forecast that Fractyl Health will post -1.66 earnings per share for the current year.

Insider Buying and Selling at Fractyl Health

In other Fractyl Health news, insider Jay David Caplan sold 22,346 shares of the business’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the sale, the insider now owns 153,544 shares of the company’s stock, valued at $277,914.64. The trade was a 12.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $238,396.99. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at $1,213,582.63. This represents a 16.42 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 274,032 shares of company stock valued at $602,979 in the last quarter.

Institutional Trading of Fractyl Health

A number of institutional investors have recently bought and sold shares of the business. BNP Paribas Financial Markets boosted its holdings in Fractyl Health by 54.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after purchasing an additional 7,397 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Fractyl Health by 27.3% during the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock worth $85,000 after acquiring an additional 8,886 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Fractyl Health during the 3rd quarter worth approximately $25,000. Rhumbline Advisers boosted its position in shares of Fractyl Health by 73.1% during the 4th quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after acquiring an additional 10,826 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after acquiring an additional 11,406 shares in the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.